Protagonist Therapeutics, Inc. (PTGX) Investor Relations Documents

Protagonist Therapeutics, Inc. (PTGX) investor relations documents from the company's IR site: 1 presentation, 22 press releases; latest deck 2022-11-08. Read in-app with summaries. First-party data.

Corporate Presentation: Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based medicines, led by its Phase 3 lead candidate, rusfertide, for PV.

Investor relations documents — source: company IR site
PublishedTypeDocument
2024-06-27Press releaseProtagonist Therapeutics Set to Join S&P SmallCap 600
2023-11-27Press releaseProtagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with D
2023-11-16Press releaseProtagonist Therapeutics Reports Granting of Inducement Awards
2023-11-09Press releaseProtagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technol
2023-11-02Press releaseProtagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-02Press releaseQ3
2023-11-01Press releaseProtagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in M
2023-11-01Press releaseProtagonist Therapeutics to Participate in Upcoming Investor Conferences
2023-10-30Press releaseProtagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
2022-11-08PresentationCorporate Presentation
2022-08-04Press releaseQ2
2022-05-04Press releaseQ1
2022-02-28Press releaseQ4
2021-11-03Press releaseQ3
2021-08-04Press releaseQ2
2021-05-04Press releaseQ1
2021-03-10Press releaseQ4
2020-11-04Press releaseQ3
2020-08-06Press releaseQ2
2020-05-07Press releaseQ1
2020-03-10Press releaseQ4
Press releasePress Releases
Press releaseInvestors

PTGX overview · PTGX earnings · PTGX financials · PTGX KPIs · PTGX documents · PTGX ownership · PTGX peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.